Abstract

The FDA recently expanded the eligibility criteria (see Table 1) for treatment with the surgically implanted hypoglossal nerve stimulation system (Inspire Upper Airway Stimulation – Inspire Medical Systems). The device has been advertised lately on radio and television.

Full Text

Published Version
Open DOI Link

Topics from this Paper

  • Inspire Medical Systems
  • Upper Airway Stimulation
  • Hypoglossal Nerve Stimulation
  • Upper Airway
  • Nerve Stimulation System
    • + Show 5 more

Create a personalized feed of these topics

Get Started

Get access to 115M+ research papers

Discover from 40M+ Open access, 2M+ Pre-prints, 9.5M Topics and 32K+ Journals.

Sign Up Now! It's FREE

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Safety and efficacy of upper airway stimulation in treatment of obstructive sleep apnea
  • Sleep Medicine
  • Dec 1, 2013
Relevant
Not Relevant
Early objective adherence to hypoglossal nerve stimulation therapy
  • Journal of Clinical Sleep Medicine
  • Feb 1, 2022
Relevant
Not Relevant
0577 PATIENT OUTCOMES AND THERAPY ADHERENCE OF UPPER AIRWAY STIMULATION FOR TREATMENT OF OSA: PRELIMINARY RESULTS FROM THE MULTI-CENTER ADHERE REGISTRY
  • Sleep
  • Apr 28, 2017
Relevant
Not Relevant
[Hypoglossal nerve stimulation in patients with CPAP failure : Evolution of an alternative treatment for patients with obstructive sleep apnea].
  • Hno
  • Feb 1, 2017
Relevant
Not Relevant
Functional outcome of tongue motions with selective hypoglossal nerve stimulation in patients with obstructive sleep apnea
  • Sleep and Breathing
  • Aug 28, 2015
Relevant
Not Relevant
Upper Airway Stimulation in OSA Patients Resolves Multilevel Airway Collapse in a Dose‐Response Manner
  • Otolaryngology–Head and Neck Surgery
  • Aug 23, 2013
Relevant
Not Relevant
0768 A Million Dreams: Improving Compliance and Treatment of Obstructive Sleep Apnea via Upper Airway Stimulation Therapy. Real-World Outcomes
  • Sleep
  • May 25, 2022
Relevant
Not Relevant
Cross motor innervation of the hypoglossal nerve\u2014a pilot study of predictors for successful opening of the soft palate
  • Sleep and Breathing
  • Jun 2, 2020
Relevant
Not Relevant
Safety and Effectiveness of Upper Airway Stimulation via the Hypoglossal Nerve for Obstructive Sleep Apnea
  • Otolaryngology–Head and Neck Surgery
  • Aug 23, 2013
Relevant
Not Relevant
Single center experience of selective upper airway stimulation in 45 patients with obstructive sleep apnea
  • Sep 1, 2016
Relevant
Not Relevant
Early feasibility of hypoglossal nerve upper airway stimulator in patients with cardiac implantable electronic devices and continuous positive airway pressure-intolerant severe obstructive sleep apnea
  • Heart Rhythm
  • Aug 1, 2018
Relevant
Not Relevant
Outcome after one year of upper airway stimulation for obstructive sleep apnea in a multicenter German post‐market study
  • The Laryngoscope
  • May 31, 2017
Relevant
Not Relevant
Selective upper airway stimulation for obstructive sleep apnea: a single center clinical experience
  • European Archives of Oto-Rhino-Laryngology
  • Sep 12, 2016
Relevant
Not Relevant
Effect of Upper Airway Stimulation in Patients With Obstructive Sleep Apnoea (EFFECT): A Randomized Controlled Crossover Trial
  • SSRN Electronic Journal
  • Jan 1, 2020
Relevant
Not Relevant
Hypoglossal nerve stimulation for obstructive sleep apnea: A review of the literature
  • World Journal of Otorhinolaryngology - Head and Neck Surgery
  • Dec 1, 2016
Relevant
Not Relevant
READ MORE FROM

The Medical letter on drugs and therapeutics

Sulbactam/durlobactam (Xacduro) for Acinetobacter pneumonia.
Just Published
  • The Medical letter on drugs and therapeutics
  • Nov 27, 2023
Relevant
Not Relevant
Shockwave therapy for erectile dysfunction.
Just Published
  • The Medical letter on drugs and therapeutics
  • Nov 27, 2023
Relevant
Not Relevant
In brief: GI effects of GLP-1 receptor agonists.
Just Published
  • The Medical letter on drugs and therapeutics
  • Nov 27, 2023
Relevant
Not Relevant
Ritlecitinib (Litfulo) for severe alopecia areata.
Open Access
Just Published
  • The Medical letter on drugs and therapeutics
  • Nov 27, 2023
Relevant
Not Relevant
Addendum.
Just Published
  • The Medical letter on drugs and therapeutics
  • Nov 27, 2023
Relevant
Not Relevant
Etrasimod (Velsipity) for ulcerative colitis.
Open Access
Just Published
  • The Medical letter on drugs and therapeutics
  • Nov 27, 2023
Relevant
Not Relevant
COVID-19 update: New Novavax vaccine formulation for 2023-2024.
  • The Medical letter on drugs and therapeutics
  • Nov 13, 2023
Relevant
Not Relevant
Correction.
  • The Medical letter on drugs and therapeutics
  • Nov 13, 2023
Relevant
Not Relevant
In brief: Empagliflozin (Jardiance) for chronic kidney disease.
  • The Medical letter on drugs and therapeutics
  • Nov 13, 2023
Relevant
Not Relevant
Antiviral drugs for influenza for 2023-2024.
  • The Medical letter on drugs and therapeutics
  • Nov 13, 2023
Relevant
Not Relevant